Olema Pharmaceuticals inc (OLMA)
10.82
-0.39
(-3.48%)
USD |
NASDAQ |
Jun 28, 16:00
10.79
-0.03
(-0.28%)
After-Hours: 20:00
Olema Pharmaceuticals Research and Development Expense (TTM): 93.20M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 93.20M |
| December 31, 2023 | 86.14M |
| September 30, 2023 | 81.85M |
| June 30, 2023 | 80.03M |
| March 31, 2023 | 89.09M |
| December 31, 2022 | 82.27M |
| September 30, 2022 | 76.66M |
| June 30, 2022 | 71.56M |
| Date | Value |
|---|---|
| March 31, 2022 | 56.42M |
| December 31, 2021 | 51.10M |
| September 30, 2021 | 41.41M |
| June 30, 2021 | 33.56M |
| March 31, 2021 | 23.60M |
| December 31, 2020 | 13.70M |
| September 30, 2020 | 8.325M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
8.325M
Minimum
Sep 2020
93.20M
Maximum
Mar 2024
59.26M
Average
71.56M
Median
Jun 2022
Research and Development Expense (TTM) Benchmarks
| Fate Therapeutics Inc | 139.10M |
| Vera Therapeutics Inc | 76.32M |
| Janux Therapeutics Inc | 53.13M |
| NovaBay Pharmaceuticals Inc | 0.061M |
| Palatin Technologies Inc | 25.13M |